Subcutaneous Epcoritamab Shows Durable Responses in Elderly B-Cell Lymphoma
Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.
BTK Degrader BGB-16673 Shows Promise in R/R WM and CLL/SLL
Findings from the phase 1/2 CaDAnCe-101 trial showed that promising ORRs in R/R WM and R/R CLL/SLL stemmed from BGB-16673 treatment.
Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM
In patients with lens-refractory multiple myeloma, cilta-cel generated deeper minimal residual disease rates across all patient subgroups.
Reduction in AEs by Pelabresib With Ruxolitinib in JAK-Naive Myelofibrosis
Pelabresib and ruxolitinib combination maintains consistent reduction of symptoms and anemia in patients with myelofibrosis.
Sonrotoclax/Zanubrutinib Combo Elicits Deep Responses for Untreated CLL/SLL
For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.
ESAs Yields Response in VEXAS Syndrome With or Without MDS
In patients with VEXAS Syndrome with or without MDS, ESAs/luspatercept generated positive hematologic improvement-erythroid responses.
Individually Optimizing Cancer Outcomes Through a Mission of Survivorship Care
A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.
Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma
Patients with newly diagnosed multiple myeloma experienced sustained MRD negativity with isatuximab/bortezomib/lenalidomide/dexamethasone.
Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma
Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.
General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma
Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.
Pafolacianine Shows No Serious Adverse Effects in Lung Cancer Surgery
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Cardiac AEs Decrease With 2nd-Generation BTK Inhibitors in B-Cell Cancers
Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.
Uproleselan Does Not Reach OS End Point, Shows Select Efficacy in AML
Phase 3 data show meaningful benefits with uproleselan in patients with primary refractory AML and post-transplant survival.
Zanubrutinib Remains Frontline Option During 5-Year Follow-Up for CLL/SLL
Zanubrutinib maintained a PFS benefit at 5 years vs benadmustine and rituximab for patients with CLL/SLL.
Data Show Long-Term Activity With Tisagenlecleucel in Follicular Lymphoma
Tisagenlecleucel shows high rates of MRD-negative status among patients with relapsed/refractory follicular lymphoma in the ELARA trial.
Venetoclax/Cladribine Improves Response Rates in AML/MDS Cohorts
The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.
Non-Relapse Mortality Rates in B-ALL and MCL Consistent With Lymphodepletion/Brexu-Cel Treatment
For patients with acute lymphoblastic leukemia and mantle cell leukemia, lymphodepletion then brexu-cel show positive efficacy and safety outcomes.
Venetoclax Plus Hypomethylating Agents Elicit Encouraging Responses in MDS
Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.
Sequencing Bispecific Agents in a Rapidly Evolving Multiple Myeloma Space
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Novel Scoring System May Improve Risk Stratification in MDS Subtype
The IPSS-del(5q) Scoring System shows that factors including male sex, cytopenias, and complex genetic background worsen the prognosis of MDS-del(5q).
Novel MDM2 Inhibitor Shows Disease-Modifying Activity in R/R Myelofibrosis
Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.
Low Dose Deferasirox Yields Promising Transfusion Independence in MDS
For patients with MDS who are relapsed/refractory to erythropoietin stimulating agents, low-dose deferasirox demonstrated promising efficacy and tolerability outcomes.
Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors
Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.
High CR Rates Noted With Zilovertamab Vedotin/R-CHP in DLBCL
Almost a 100% complete response rate was noted with Zilovertamab Vedotin/R-CHP for patients with DLBCL.
Maintenance Teclistamab Yields Preliminary Activity in NDMM
All evaluable patients achieved minimal residual disease negativity following teclistamab-based treatment in the phase 3 MajesTEC-4/EMN30 trial.
PFS Significantly Improves With Acalabrutinib Regimen in Untreated CLL
Acalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.
PFS, OS Significantly Improved by Daratumumab for Smoldering Multiple Myeloma
PFS and OS were significantly improved with subcutaneous daratumumab vs active monitoring in patients with smoldering multiple myeloma.
Positive Efficacy and Safety Outcomes Result from Second-line Liso-cel in LBCL
For patients with relapsed/refractory large B-cell lymphoma, PFS and OS data from CD-19-directed, 4-1BB CAR T-cell Liso-cel therapy were consistent with prior results.
Asciminib Boosts Efficacy Vs TKIs in Chronic Myeloid Leukemia
Data from the phase 3 ASC4FIRST trial support asciminib as a standard of care in newly diagnosed chronic myeloid leukemia in chronic phase.
Across All Age Groups, Brexu-Cel Remains Efficacious in R/R B-ALL
Patients aged 60 to 69 years old had comparable efficacy when treated with brexu-cel for relapsed/refractory B-cell ALL.
